CSL Behring LLC
Records under this name other than the patents CSL Behring LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,534,029 | Method of Purifying Proteins Formerly held In force · High confidence | In force | High confidence | |
| US 11,814,421 | Truncated von Willebrand Factor polypeptides for treating hemophilia Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,396,943 | Hemopexin formulations Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,325,738 | Treatment of CIDP Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,357,689 | Methods of Treating or Preventing a Cardiovascular System Complication of Sickle Cell Disease with an Anti-G-Csfr Antibody Formerly held In force · High confidence | In force | High confidence | |
| US 7,777,006 | Method for Purification of ALPHA-1-Antitrypsin Term ended Term ended Feb 22, 2026 · High confidence | Term ended | Term ended Feb 22, 2026 | High confidence |
| US 10,918,696 | Methods of Treatment Using Hemopexin Compositions Formerly held Lapsed on the fee record Ended Feb 16, 2025 · High confidence | Lapsed on the fee record | Ended Feb 16, 2025 | High confidence |
| US 11,224,643 | Methods of Treatment Using ALPHA-1-Antitrypsin Compositions Term ended Term ended Jan 11, 2024 · High confidence | Term ended | Term ended Jan 11, 2024 | High confidence |
| US 8,124,736 | Alpha 1- Antitrypsin Compositions Term ended Term ended Dec 31, 2022 · High confidence | Term ended | Term ended Dec 31, 2022 | High confidence |
| US 8,722,624 | ALPHA-1-Antitrypsin Compositions and Methods of Use Term ended Term ended Dec 31, 2022 · High confidence | Term ended | Term ended Dec 31, 2022 | High confidence |